Details

Autor(en) / Beteiligte

• Grabar, Sophie
• Potard, Valérie
• Piroth, Lionel
• Abgrall, Sophie
• Bernard, Louis
• Allavena, Clotilde
• Caby, Fabienne
• de Truchis, Pierre
• Duvivier, Claudine
• Enel, Patricia
• Katlama, Christine
• Khuong, Marie-Aude
• Launay, Odile
• Matheron, Sophie
• Melica, Giovanna
• Melliez, Hugues
• Meynard, Jean-Luc
• Pavie, Juliette
• Slama, Laurence
• Bregigeon, Sylvie
• Tattevin, Pierre
• Capeau, Jacqueline
• Costagliola, Dominique

Titel

Striking differences in weight gain after cART initiation depending on early or advanced presentation: results from the ANRS CO4 FHDH cohort

Ist Teil von

• Journal of antimicrobial chemotherapy, 2023-03, Vol.78 (3), p.757-768

Ort / Verlag

US: Oxford University Press

Erscheinungsjahr

2023

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Abstract Background Many studies have reported weight gain in ART-naive people living with HIV (PWH) initiating an integrase strand-transfer inhibitor-based regimen. We studied the impact of early or advanced presentation and that of individual drugs in PWH initiating combined ART (cART) between 2012 and 2018. Methods From the French Hospital Database HIV cohort, we assessed factors associated with a weight gain  ≥10%, weight change after cART initiation or BMI increase  ≥5 kg/m2 up to 30 months. The analyses were conducted overall, and among PWH with early (primary infection or CD4 >350/mm3 and viral load  <100 000 copies/mL, without AIDS) and advanced presentation (AIDS or CD4 <200/mm3, not during primary infection). Results At 30 months, 34.5% (95% CI: 33.5–35.6) of the 12 773 PWH had a weight gain ≥10%, with 20.9% (95% CI: 19.6–22.2) among the 5794 with early presentation and 63.1% (95% CI: 60.9–65.3) among the 3106 with advanced presentation. Weight gain was 2.8 kg (95% CI: 2.0–3.7) for those with early presentation and 9.7 kg (95% CI: 8.4–11.1) for those with advanced presentation. Most weight gain occurred in the first 12 months. Underweight and obese PWH were at significantly higher risk of a BMI increase  ≥5 kg/m2 than normal-weight PWH. Results differed within classes and by outcome. Raltegravir and dolutegravir were consistently associated with greater weight gain than the other third agents. Tenofovir alafenamide was also associated with higher weight gain than tenofovir disoproxil or abacavir. Conclusions After initiating cART, PWH with early presentation exhibited a small weight gain, whereas it was large among those with advanced presentation. The choice of ART should account for the risk of weight gain, especially for PWH who present with advanced disease and/or are obese.